Project Grant R21NS142761
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Van Andel Research Institute $123,163 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective June 1, 2025, with completion targeted for September 26, 2025. The project focuses on identifying cortical neuronal vulnerability and resilience in Parkinson's disease, specifically investigating which neurons are susceptible to misfolded...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This exploratory research project, scheduled for completion by May 31, 2027, investigates the roles of the deubiquitylation pathway in TDP-43 (TAR DNA-binding protein 43) pathology relevant to...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $438,625 Project Grant to the University of California, San Diego on August 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research initiative, extending through July 31, 2027, investigates a novel neuroprotective mechanism against ischemic brain injury by characterizing "actinification"—a pro-survival...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a Project Grant award of $229,078 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 11, 2025, with a completion date of July 31, 2030. This five-year research initiative focuses on ferroptosis sensitization in glioblastoma (GBM), the most common primary...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $595,047 to the University of California, Los Angeles on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This five-year project grant supports fundamental research investigating non-apoptotic cell death mechanisms in glioblastoma (GBM), specifically focusing on a newly identified form of cell death termed...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $521,839 to the University of California, San Diego on August 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This five-year project grant, scheduled for completion by July 31, 2030, supports fundamental research investigating the mechanisms of pathogenic microglial populations in central nervous system (CNS)...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $227,205 Project Grant award dated May 9, 2025, from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research project, which extends through April 30, 2030, examines the effects of the Parkinson's Disease-associated protein LRRK2 (leucine-rich repeat kinase 2) on lysosomal...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $149,264 to Indiana University Indianapolis on December 5, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award supports a research project investigating neutrophil contributions to cognitive impairment in a comorbid model combining Alzheimer's Disease (AD) and Vascular Contributions to Cognitive Impairment and...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Columbia University's Health Sciences Division a $649,638 Project Grant effective August 1, 2025, through July 31, 2030, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This research initiative aims to develop innovative methodologies for accelerating the maturation of stem cell-derived neurons by engineering alternative...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Leland Stanford Junior University a project grant of $223,665 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) effective July 1, 2025, through June 30, 2030. Principal Investigator Dr. Rebecca Levy will conduct research to elucidate how CACNA1C gene variants cause interneuron pathophysiology and cortical network dysfunction. The...
Loma Linda University received a $251,687 Project Grant award on February 15, 2026, from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating ferroptosis—an iron-dependent cell death pathway—as a potential convergence mechanism driving neurodegeneration in Niemann-Pick Disease Type C (NPC), a fatal pediatric neurodegenerative disorder affecting fewer than 200,000 individuals globally. The research project, scheduled for completion by January 31, 2028, will characterize ferroptotic activation patterns along the anterior-to-posterior axis of cerebellar neurodegeneration in NPC and evaluate the therapeutic efficacy of two anti-ferroptotic compounds (J147 and CMS121) in reducing disease pathology. This investigator-initiated research project advances NINDS's mission to reduce the burden of neurological disease by addressing a critical gap in understanding how diverse NPC cellular pathologies—including endo-lysosomal enlargement, mitochondrial damage, iron dysregulation, and chronic inflammation—converge to drive disease progression. The deliverables include mechanistic characterization of ferroptosis in NPC models and preclinical evaluation of anti-ferroptotic therapeutics, with potential applications toward developing disease-modifying treatments for this currently incurable condition with no approved therapies in the United States.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $251.7k | 2/13/26 |